Stock Events

Stock Events

Photocure ASA 

$6.01
15
-$0.62-9.35% Tuesday 20:00

Statistics

Day High
6.63
Day Low
6.63
52W High
7.39
52W Low
5.58
Volume
100
Avg. Volume
66
Mkt Cap
163M
P/E Ratio
19.39
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 13
$0.35
Dec 9
$0.72
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

28OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.05
-0.03
-0.01
0.01
Expected EPS
N/A
Actual EPS
N/A

Financials

-0.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
52.3MRevenue
-140,759.55Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHCUF. It's not an investment recommendation.
Yara International ASA.
6
YAR.OL
Apple
3
AAPL
Microsoft
3
MSFT
Amazon
3
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie competes in the bladder cancer space with treatments that could be seen as alternatives to Photocure's diagnostic solutions.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG offers a range of oncology treatments, including diagnostics and therapeutics that could compete with Photocure's bladder cancer detection and treatment products.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol-Myers Squibb has a portfolio of oncology products that could serve as alternatives to Photocure's offerings, particularly in the bladder cancer segment.
Merck
MRK
Mkt Cap376.37B
Merck & Co., Inc. provides a variety of cancer treatments, including immunotherapies that could compete with Photocure's bladder cancer solutions.
Pfizer
PFE
Mkt Cap159.99B
Pfizer Inc. has a broad oncology portfolio, including treatments for bladder cancer that could compete with Photocure's products.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca PLC has a strong presence in the oncology market, including treatments that could compete with Photocure's bladder cancer diagnostics and therapeutics.
Novartis
NVS
Mkt Cap301.95B
Novartis AG offers a wide range of cancer treatments, including therapies for bladder cancer that could be seen as competitive to Photocure's products.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops oncology treatments that could compete with Photocure's bladder cancer solutions.
GSK
GSK
Mkt Cap104.97B
GlaxoSmithKline plc has a portfolio of oncology products, including treatments for bladder cancer that could compete with Photocure's offerings.
Sanofi
SNY
Mkt Cap109.86B
Sanofi offers oncology treatments, including those for bladder cancer, that could serve as alternatives to Photocure's diagnostic and therapeutic products.

About

Photocure ASA, a specialty pharmaceutical company established in Oslo, Norway in 1993, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing, distribution, and commercialization. The company's reach extends across the Nordic countries, major European markets like Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, as well as the United States. Key offerings include Hexvix/Cysview, which is used for the identification and ongoing care of bladder cancer. Additionally, Photocure is currently developing Cevira, a treatment designed for human papillomavirus (HPV) infections and precancerous lesions of the cervix. Its products are supplied to pharmaceutical wholesalers, pharmacies, and hospitals primarily through strategic licensing partnerships.
Show more...
CEO
Daniel Schneider
Employees
101
Country
Other
ISIN
NO0010000045
WKN
000931150

Listings

ST
SE
PHOO.ST
STU
DE
PHS.STU
LSE
GB
0IMT.LSE
OTC Link
US
PHCUF

0 Comments

Share your thoughts

FAQ

What is Photocure ASA stock price today?▼
The current price of PHCUF is $6.01 USD — it has decreased by -9.35% in the past 24 hours. Watch Photocure ASA stock price performance more closely on the chart.
What is Photocure ASA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Photocure ASA stocks are traded under the ticker PHCUF.
Is Photocure ASA stock price growing?▼
PHCUF stock has risen by +0% compared to the previous week, the month change is a -9.35% fall, over the last year Photocure ASA has showed a +2.3% increase.
What is Photocure ASA market cap?▼
Today Photocure ASA has the market capitalization of 163M
When is the next Photocure ASA earnings date?▼
Photocure ASA is going to release the next earnings report on October 28, 2026.
What were Photocure ASA earnings last quarter?▼
PHCUF earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -250% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Photocure ASA revenue for the last year?▼
Photocure ASA revenue for the last year amounts to 52.3M USD.
What is Photocure ASA net income for the last year?▼
PHCUF net income for the last year is -140,759.55 USD.
Does Photocure ASA pay dividends?▼
Yes, PHCUF dividends are paid en. The last dividend per share was 0.35 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Photocure ASA have?▼
As of August 26, 2026, the company has 101 employees.
In which sector is Photocure ASA located?▼
Photocure ASA operates in the Health & Wellness sector.
When did Photocure ASA complete a stock split?▼
Photocure ASA has not had any recent stock splits.
Where is Photocure ASA headquartered?▼
Photocure ASA is headquartered in Oslo, Other.